Does Timing of Surgery Affect Rectal Cancer Outcomes? Does Timing of Surgery Affect Rectal Cancer Outcomes?
Waiting more than 12 weeks for surgery following neoadjuvant therapy was associated with improved tumor regression grade and reduced risk of systemic recurrence but not overall survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer? Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer?
Neoadjuvant chemoradiotherapy can be omitted in low-risk rectal cancer patients without compromising outcomes, but intensified in high-risk patients, new findings suggest.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 27, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Neoadjuvant Immunotherapy for CRC: Too Good to Be True? Neoadjuvant Immunotherapy for CRC: Too Good to Be True?
Breakthrough findings on the effectiveness of neoadjuvant immunotherapy could help usher in a new treatment paradigm for colorectal cancer.Journal of Oncology Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Deep-learning CT model helps predict ovarian cancer treatment response
A deep-learning model using CT images can predict neoadjuvant chemotherapy respons...Read more on AuntMinnie.comRelated Reading:
Radiomic features on CT help classify ovarian cancer subtypes
MRI has upper hand on CT for ovarian cancer detection
Body composition foretells ovarian cancer treatment complications
CT/ultrasound fusion enhances ovarian biopsies
Cinematic rendering enhances pelvic CT bone evaluation (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 26, 2023 Category: Radiology Source Type: news
Episode 1: The Role of Adjuvant and Neoadjuvant Therapy in Melanoma Episode 1: The Role of Adjuvant and Neoadjuvant Therapy in Melanoma
Drs Sapna Patel and Matteo Carlino dive into the data and consider the current and future roles of adjuvant and neoadjuvant therapy.Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 15, 2023 Category: Surgery Tags: Hematology-Oncology InDiscussion Source Type: news
ASCO: FOLFOX Noninferior to Chemoradiotherapy for Overall Survival in Rectal Cancer
FRIDAY, June 9, 2023 -- Neoadjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is noninferior to preoperative chemoradiotherapy with respect to overall survival for patients with locally advanced rectal cancer who are... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2023 Category: Pharmaceuticals Source Type: news
Omitting RT Safe in Many Locally Advanced Rectal Cancers
(MedPage Today) -- CHICAGO -- Standard pelvic chemoradiotherapy prior to surgery can be safely omitted in select patients with locally advanced rectal cancer whose tumors respond to neoadjuvant chemotherapy, findings from a large cooperative... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 5, 2023 Category: Gastroenterology Source Type: news
Neoadjuvant Chemo Flops Versus Upfront Surgery for Resectable Pancreatic Cancer
(MedPage Today) -- CHICAGO -- Neoadjuvant chemotherapy failed to match upfront surgery for survival in resectable pancreatic cancer, a small randomized trial showed.
Unexpectedly, patients assigned to surgery first lived more than a year longer... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - June 4, 2023 Category: Surgery Source Type: news
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
This study evaluates an investigational combination regimen of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) for newly diagnosed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), (Abstracts #7535 and #P617, respectively).Advancing the Science of Solid Tumors Through Precision MedicineJanssen’s continued innovation in solid tumors focuses on advancing precision medicine options for patients with biomarker-driven disease who have limited targeted treatment options and moving patients into earlier lines of therapy when treatments may be more effective. Lung CancerAn oral presentation will report ...
Source: Johnson and Johnson - May 18, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
AACR: Neoadjuvant, Adjuvant Durvalumab Beneficial for NSCLC
MONDAY, May 1, 2023 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant and adjuvant durvalumab offers benefits in terms of pathologic complete response and event-free survival (EFS), according to a study presented at the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 1, 2023 Category: Pharmaceuticals Source Type: news
No Survival Benefit With NAC for Advanced Stomach Cancer No Survival Benefit With NAC for Advanced Stomach Cancer
Neoadjuvant chemotherapy did not improve survival in elderly patients undergoing gastrectomy for advanced gastric cancer. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 21, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Durvalumab Pre, Post Surgery in NSCLC: Practice Changing? Durvalumab Pre, Post Surgery in NSCLC: Practice Changing?
The AEGEAN trial is the second phase 3 study, after Checkmate 816, to demonstrate a benefit from neoadjuvant immunotherapy for patients with resectable non –small cell lung cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 20, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Ovarian Cancer: Key Abstracts From SGO 2023 Ovarian Cancer: Key Abstracts From SGO 2023
Key data in ovarian cancer presented at SGO 2023 include a reassessment of niraparib, olaparib as neoadjuvant therapy, and options in platinum-resistant disease, as reported by Dr Shannon Westin.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 18, 2023 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news
'Potential' New Option for Operable NSCLC
(MedPage Today) -- ORLANDO -- The addition of durvalumab (Imfinzi) to neoadjuvant chemotherapy followed by adjuvant treatment with the PD-L1 inhibitor alone could become a new standard option for resectable non-small cell lung cancer (NSCLC)... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 17, 2023 Category: Hematology Source Type: news
More Data Needed for Neoadjuvant Tx for Bile Duct Cancer More Data Needed for Neoadjuvant Tx for Bile Duct Cancer
In a debate held recently on the use of neoadjuvant therapy for high-risk intrahepatic cholangiocarcinoma, both sides agreed that more research is needed.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 5, 2023 Category: Surgery Tags: Hematology-Oncology News Source Type: news
